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ABSTRACT
This article aims to describe the clinical features of electric powered indoor/outdoor wheelchair
(EPIOC) users with cerebral palsy (CP) that are problematic to optimal prescription and to explore
comorbidities, features of CP, and conditions secondary to disability impacting on equipment provi-
sion for children and adults. The method is a cross-sectional study of EPIOC users (n = 102) with a
primary diagnosis of CP. This is a retrospective review of electronic and case note records of EPIOC
recipients attending a specialist wheelchair service in 2007–2008. Records were reviewed by a
rehabilitation consultant. Data were extracted under three themes; demographic, diagnostic/clinical
and wheelchair factors. There were 48 males mean age 27.5 (range 8–70, SD 13.9) years and 54
females, mean age 29.5 (range 7–68, SD 14.6) years with CP. Sixteen comorbidities, nine features of CP,
and five features of disability influenced wheelchair prescription. Sixty-four users were provided with
specialized seating (SS) and 47 with tilt-in-space (TIS) seats. Complex controls were provided to 16
users, 12 tray-mounted. The majority of users had both SS and TIS. Powered wheelchair prescription
has important therapeutic roles in clinical management in addition to enhancing mobility, indepen-
dence and participation. Clinical features such as spasticity and problematic pain appeared less well
managed in adults than in children.
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Cerebral palsy (CP) is an umbrella term for a group of long term
non-progressive but often changing neurological conditions
(Aisen et al., 2011) affecting approximately 2.0 per 1,000 live
births in developed countries (Rosenbaum, 2014). It occurs due
to brain damage either before, during, or after birth (Parkes,
Donnelly, & Hill, 2001) and is thought to include a genetic
component (Tollanes,Wilcox, Lie, &Moster, 2014).Most people
with CP now have a normal life span (Aisen et al., 2011; Parkes
et al., 2001) and the number of adults is increasing due to
improved survival of premature infants and increased age in
the general population (Haak, Lenski, Hidecker, Li, & Paneth,
2009; Zaffuto-Sforza, 2005).
Approximately one third of children with CP are non-
ambulatory (Novak, Hines, Goldsmith, & Barclay, 2012) and
37% of adults with CP use powered wheelchairs (Andersson &
Mattsson, 2001). The benefits offered by powered mobility
such as enhanced independence (Davies, De Souza, & Frank,
2003) and increased participation in education, (Evans,
Neophytou, De Souza, & Frank, 2007) employment, and social
life (Zaffuto-Sforza, 2005) are well established. Even young
children provided with powered mobility gain benefits in
social, language, and play skills (Rosenbaum, 2003) while the
benefits for adults are mainly the maintenance of independence
and self-care (Zaffuto-Sforza, 2005).
For those with severely disabling CP, these benefits may be
achieved by the additional use of specialized seating (SS) systems
(adaptive seating) (Angsupaisal, Maathuis, & Hadders-Algra,
2015) which may incorporate enhanced features, e.g., tilt-in-
space (TIS) (Dicianno et al., 2015). It has been proposed that
the primary focus of provision of assistive technologies (ATs) is
not only the maintenance of skeletal integrity, the therapeutic
value of powered chairs (e.g., for pain relief; Dicianno et al.,
2015) but also to improve functional ability and participation
(Angsupaisal et al., 2015). A combination of powered mobility
devices, enhanced wheelchair features, SS, and complex control
systems may be needed to achieve these aims (Zupan & Jenko,
2012).
The systematic review of Novak et al. (2012) provided
clinical recommendations for mobility assessment and provi-
sion in adolescents with CP. This review also identified a
range of “co-occurring impairments, diseases and functional
limitations” experienced by individuals with CP that impacted
on their disability (Novak et al., 2012). These co-occurring
clinical conditions are likely to change over time influencing
the wellbeing of individuals and their rehabilitation needs
(Novak et al., 2012). The long-term consequences of CP are
further complicated by growth and aging (Kembhavi, Darrah,
Payne, & Plesuk, 2011). CP is now considered a lifespan
condition with associated health factors, e.g., musculoskeletal
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impairments, medical complications, speech impairments,
pain, and fatigue (Kembhavi et al., 2011). It is unclear if
these are part of the natural course of CP, a consequence of
long-term disability, or unrelated comorbidity.
Comorbidity has been defined as “any distinct additional entity
that has existed ormay occur during the clinical course of a patient
who has the index disease under study” (Feinstein, 1970).
Complication is considered to be a condition that co-exists or
follows the index condition (Valderas, Starfield, Sibbald,
Salisbury, &Roland, 2009). A clear differentiation between comor-
bidities, consequences of long-term disablement, and clinical fea-
tures associated with CP may be complex and imprecise as
reported for multiple sclerosis (De Souza & Frank, 2015) and
rare diseases (De Souza & Frank, 2016). For example, epilepsy in
those with CPmay be considered a “co-occurring disease” (Novak
et al., 2012), a co-morbidity (Govender, Hepworth, Bagwandeen,
& Chetty, 2015), or a common symptom of CP (Zenczak-Praga,
Zgorzalewicz-Stachowiak, & Cesar, 2015). Consequently it has
been suggested that these clinical factors may be considered col-
lectively as additional clinical features (ACFs) (De Souza & Frank,
2015).
In the United Kingdom, the National Health Service (NHS)
provides electric powered indoor/outdoor wheelchairs
(EPIOCs) to people with severe/complex disabilities fulfilling
strict criteria (Frank, Ward, Orwell, McCullagh, & Belcher,
2000).Those eligible for provision of an EPIOC by the NHS
must be are unable to walk around their home unaided, cannot
self-propel a manual wheelchair, but are able to operate the
powered chair independently and safely. These criteria for
EPIOC provision in the NHS are most likely to relate to indivi-
duals with CP having Gross Motor Function Classification
System (GMFCS) level IV, defined as “self-mobility with limita-
tions; children are transported or use power mobility outdoors
and in the community” (Palisano et al., 1997). Some individuals
defined as level V who “achieve self-mobility using a power
wheelchair with extensive adaptations” (Palisano et al., 1997)
may be provided with an EPIOC. Although the GMFCS was
developed to describe children, they have been found to be
helpful for adults with CP (McCormick et al., 2007).
Many body systems are affected during the growth of a
child with CP with a high risk of developing secondary
conditions (Kembhavi et al., 2011). The interaction between
the aging process and CP is poorly understood, particularly
for those unable to walk (Haak et al., 2009). The challenge for
powered mobility service providers is to prescribe equipment
that maximizes functional potential yet simultaneously
manages the risk of developing secondary conditions.
Evidence on the management of those with comorbidity is
limited (Smith, Soubhi, Fortin, Hudon, & O’Dowd, 2012).Thus
the aims of this study are to describe the clinical features of
EPIOC users with CP of all ages and explore the complexities
of comorbidities, CP features, and conditions secondary to
disability impacting on powered wheelchair provision and
clinical management.
Methods
This is a cross-sectional study of a NHS clinic population and
was approved by the National Research Ethics Service.
The service
A specialist NHS service was established for the provision of
EPIOCs in 1997 to co-exist with the pre-existing Special
Seating Service at the hospital. This Specialist Wheelchair
Service (SWS) served a population of around 3.1 million
people from both rural and inner city areas. All the therapists
and engineers were full-time wheelchair professionals and
were supported by three part-time rehabilitation medicine
consultants. Users were referred by the local NHS wheelchair
services for assessment of suitability for an EPIOC which
involved:
(1) Assessment by the locality-based occupational thera-
pist for the suitability of the home environment for
the EPIOC prescription and that eligibility criteria
(Frank et al., 2000) would be fulfilled. Referral to
the SWS included a full medical history and details
of the home environment.
(2) Children (those under 19 years) were also assessed by
their paediatric therapist to provide details of current
management and an evaluation of cognitive,
emotional, visuospatial and physical development
relating to their suitability for EPIOC driving.
(3) The clinic assessment involved a review of the medical
history and relevant social situation (including the home
environment suitability for EPIOC use). Visual fields
were examined by confrontation, the individual was
weighed and physical examinations (in sitting and
lying) were performed to identify potential problems
with posture/seating or controlling an EPIOC. Transfers
were observed for safety and for pain and/or spasticity.
(4) An EPIOC driving assessment included crossing a
street and negotiating uneven surfaces, potholes, and
kerbs. Consideration was given for the safety of the
user and others whilst ensuring satisfactory control of
the wheelchair. Age-appropriate supervision of chil-
dren was accounted for. Following these assessments,
an optimal EPIOC and cushion were prescribed.
(5) A rehabilitation engineer from the SWS delivered the
EPIOC, usually to the user’s home, explained its
features, checked seating, and that driving appeared
satisfactory in the user’s home and outdoors.
Community living EPIOC users relevant to this research
had a diagnosis of CP. Data consisting of demographic data,
clinical issues, and wheelchair factors were entered into
electronic records and reviewed between June 2007 and
September 2008 by a consultant physician in rehabilitation
medicine. They were systematically extracted and entered into
a database. Further data were entered from clinical notes
(charts) and anonymized by removing names, addresses, and
any unique identifier, e.g., hospital identifying number.
Demographic profiles consisted of age at initial assessment
and gender. The type of CP was classified into predominantly
spastic, dyskinetic, and ataxic groups (Cans et al., 2007).
Where a predominant type of CP was not identified, it was
classified “unclear.” Where the database held no information,
it was classified as “unknown.”
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Clinical profiles included comorbidities, complications relat-
ing to CP, or disability. Due to the ambiguity which some clinical
features may reflect either the CP itself, co-morbidity or a
complication of disability, they were grouped as ACFs when
referred to collectively (De Souza & Frank, 2015, 2016).
All impairments noted by Novak et al. (2012), in a systematic
review with meta-analysis of 30 studies on CP, were categorized
as disease related. We added spasticity as a feature of CP
although omitted by Novak et al. (2012). Spasticity is a common
feature of CP. In the context of this research, spasticity was noted
as “problematic” when it interfered with the EPIOC prescrip-
tion, e.g., stability in the chair (Lacoste, Therrien, & Prince,
2009), increased risk of contracture or pressure ulcers
(Noonan, Jones, Pierson, Honkamp, & Leverson, 2004), and
musculoskeletal deformity and dysfunction (Liptak, 2008).
Users with pain requiring further investigation/management,
or influencing the EPIOC prescription were recorded as “pro-
blematic pain,” as noted by Novak et al. (2012). Those noted by
others as being disability related were spinal deformities
(Kembhavi et al., 2011; kyphus, scoliosis, and kyphoscoliosis
were all noted as kyphoscoliosis), osteoporosis (Kim et al.,
2015), oedema/cellulitis (Zaffuto-Sforza, 2005), thromboembo-
lism (Ohmori et al., 2013), pelvic obliquity (Krautwurst et al.,
2013), and pressure sores (Janicki, Henderson, & Rubin, 2008).
Conditions classified as comorbidities were those considered
unrelated to CP.
Wheelchair factors included information about SS, defined as
“that which is needed by people who require a wheelchair but
due to instability or deformity need additional support in order
to function” (British Society of Rehabilitation Medicine, 2004, p.
7). Other data included TIS, cushions, and complex controls.
Methods of analysis
This was a secondary data analysis of a sub-group of EPIOC
users from a cohort reported elsewhere (Frank & De Souza,
2013). Descriptive statistics were used to analyze demographic
and wheelchair data.
Results
A diagnosis of CP was found for 102 users, mean age 28.6
(range 7–70, SD ±14.2) years (Table 1), comprising 48 males
mean age 27.5 (range 8–70, SD ±13.9) years and 54 females,
mean age 29.5 (range 7–68, SD ±14.6) years. Twenty-three
were under 19 years of age (Table 1), two aged under 10, and
two aged 65 or over. Users were reviewed a mean of 76 (range
0–133) months after EPIOC assessment. Partial data were
available on the medical profiles of 13 users whilst TIS data
were available for 90 users. Only 28 users had CP as a single
diagnosis, whilst 36 had one ACF and 38 had two or more
(Table 1).
The majority had spastic (n = 44) or dystonic CP (23 with
observed athetoid movements, five referred with dystonia).
Ten users were categorized “unclear;” six low-toned (two
related to hip surgery), two hemiplegic (not spastic), and
two “mixed—spastic and athetoid.” There were insufficient
data to classify 21 users (Table 2).
Two users were mothers. One, who had difficulty caring
for her 9-year-old child, had dystonic CP with problematic
pain and spasticity complicated by recurrent deep venous
thromboses (on Warfarin) and asthma. The other, with
small children, had problematic back pain associated with
kyphoscoliosis, severe oedema, and chronic cellulitis.
Comorbidities
Sixteen comorbidities were identified with asthma and
osteoarthritis being the commonest (Table 3). Five users had
congenital conditions (two hydrocephalus and one each with
cystic fibrosis, congenital heart disease, and familial spastic
paraplegia). Three adults had depression.
CP disease-related impairments
We found nine features of CP, of which eight were reported by
Novak et al. (2012), the most frequent being problematic pain
(n = 20), hip problems (n = 18), and problematic spasticity
(n = 15) (Table 3). Specified causes of problematic pain were
spasticity (n = 7), (kypho)scoliosis (n = 6), back pain (n = 5), hip
pain (n = 2), back pain, and spasticity (n = 2), no specified cause
(n = 4), or more than one of the above. Nine users reported back
pain thought to be treatable with standard approaches.
Thirteen users had problematic spasticity (12 aged 19 or
older—Table 1), two had contractures complicating manage-
ment and one had a large ischial pressure sore. We also found
epilepsy such that driving was not contraindicated (n = 8).
Fatigue was not reported.
Complications of disability
(Kypho)scoliosis was the commonest complication of disability
(n = 21 mean age 25.1, SD ±14.2, range 7–68 years; Table 1)
Table 1. Features of children aged 0–18 and adults aged 19+ with CP.
Age 1–18 Age 19+ Total
Number (Number of males) 23 (11) 79 (37) 102 (48)
Mean age (range) 14.7 (7–18) 32.6 (19–70) 28.6 (7–70)
Special seating 21 (91.3%) 43 (54.4%) 64 (62.7%)
TIS* 12 (60%) 35 (50%) 47 (52.2%)
Complex controls 5 (21.7%) 11 (13.9%) 16 (15.7%)
Features of CP
None 14 37 51
One 7 23 30
Two or more 2 19 21
Athetosis 7 16 23
Problematic pain 1 19 20
Hip problems 4 14 18
Spasticity 1 12 13
Comorbidities
None 16 56 72
One 7 18 25
Two or more 0 5 5
Complications of disability
None 16 61 77
One 7 16 23
Two or more 0 2 2
(Kypho)scoliosis 7 14 21
Total ACFs
None 5 23 28
One 12 24 36
Two or more 6 32 38
Note. *No data on 12 users (three <18; nine 19+).
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managed with SS (n = 19) and TIS (n = 12). Three users had
pressure sores, one user had oedema and cellulitis, and another
user had thromboembolic disease (see above and Table 3).
Problematic ACFs requiring further medical management
were found in 47 users who were referred to their family
doctors. Of these, 18 required medical management for proble-
matic pain, 16 for (kypho)scoliosis and three each for spasticity
and hip problems.
Wheelchair factors
Data on TIS were available for 90 users of whom 47 (52%)
used TIS. Sixty-four (63%) users had SS and 40 (44%) had
both SS and TIS (Table 2). Two users under 19 years, both
having spastic CP without ACFs, did not have SS (Table 1).
Sixteen users, five under 19 years, had complex control
systems (Table 1) of which 12 were tray mounted, eight
were non-standard, and nine had controls interfacing with
other AT, e.g., environmental control systems. Nine users
with complex controls were provided with both SS and TIS.
The most common SS provided were CAPS 11 (seating
system for postural management which allows for growth;
n = 12; mean age 16, range 7–26, SD ±6.1 years), carved
foam (n = 10; mean age 29.5, range 20–45, SD ±9.4 years),
and Scott Seating (a modular seating system; n = 9; mean age
21.3, range 13–45, SD ±9.4 years). Two users were prescribed
Matrix seating and two molded seat inserts. Users aged 18 or
less were provided with SS more often than those aged 19 or
more (Table 1).
The most common cushions provided were Qbitus
(bespoke pressure reduction; n = 29, mean age 32.2, range
14–70, SD ±16.3 years), Jay 2 (n = 13; mean age 29.4, range
Table 3. Features of CP and disease-related impairments, comorbidities and complications of disability of 102 EPIOC users compared to published impairments for CP.
Impairments noted by Novak et al.







For those able to walk, neck, back,
and feet are high risk pain sites
Problematic pain 20
Back pain 11
Hip dislocation Hip dislocation/other hip 18





Intellectual impairment Learning impairment 4
Hearing impairments






High risk for malnutrition Weight loss2








Congenital heart disease 1
Tenosynovitis 1
Chronic fatigue syndrome 1
Migraine 1
Discoid Lupus 1
Familial spastic paraplegia 1
Bladder control Urinary incontinence 1
Cystic fibrosis 1
Knee arthrodesis 1
Table 2. Categories of 102 CP EPIOC users by age, gender, use of SS, and TIS; problematic pain, scoliosis, spasticity, and hip problems.
CP category N (N of men) Mean age (±SD) years
N under age
19 years SS N TIS N*
SS and







Spastic 43 (23) 26.6 (14.4) 10 29 26 22 10 12 11 9
Dystonic 28 (13) 27.2 (13.2) 9 19 11 10 2 5 4 4
Unclear 10 (5) 26.2 (17.8) 3 8 4 3 5 0 2 0
Not known 21 (7) 35.6 (12.2) 1 8 6 5 4 3 1 0
Total 102 (48) 28.6 (14.2) 23 64 (63%) 47 (52%) 40 (44%) 21 20 18 13
Note. Number with unknown TIS use = 12.
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18–51, SD ±13.1 years) and standard cushions (n = 12: mean
age 29.2, range 12–60, SD ±14.2 years).
Discussion
This study is the first to describe a cohort of individuals with CP
GMFCS levels IV and V, irrespective of age, prescribed an
EPIOC. It highlights issues considered most relevant to aging
with CP, namely, mobility, pain, fatigue, and comorbidity (Haak
et al., 2009). Our cohort is atypical, mostly excluding those with
learning/intellectual impairments and not including children of
preschool age (Frank & De Souza, 2013). It excludes those able
to walk and self- propel and thus includes a high proportion of
users with spastic tetraplegia. Six users with predominant hypo-
tonicity did not fit into the categorization of Cans et al. (2007)
and were grouped “unclear” although others consider hypoto-
nicity as a notable feature of CP (Aisen et al., 2011; Shevell,
Dagenais, & Hall, 2009).
Problematic features of CP
Problematic pain is a major issue for children, young people
(Novak et al., 2012; Penner, Xie, Binepal, Switzer, & Fehlings,
2013) and adults (Opheim, Jahnsen, Olsson, & Stanghelle, 2009)
with CP. Our finding that problematic pain was predominately in
adults may reflect deterioration in the underlying CP (Opheim
et al., 2009) inadequate management (Noonan et al., 2004;
Zaffuto-Sforza, 2005) or both. Provision of an EPIOC can be
used to reduce users’ pain when first provided (Davies et al.,
2003). Although a similar service was provided for both adults
and children, childrenmay have been seenmore often due to their
growth indicating wheelchair adjustments were needed.
Problematic pain in EPIOC users may reflect pain relating
to their underlying medical condition, their wheelchair and seat-
ing or a combination of the two (Frank, De Souza, Frank, &
Neophytou, 2012). The problematic pain may also relate to spas-
ticity (Aisen et al., 2011; Zaffuto-Sforza, 2005), dislocated hips
contributing to back pain and/or spasticity, (Van Der Slot et al.,
2012), scoliosis, and/or prolonged sitting (Frank et al., 2012).
Although problematic neck pain is a noted feature of CP
(Jahnsen, Villien, Aamodt, Stanghelle, & Holm, 2004; Novak
et al., 2012) our users were routinely provided with neck
restraints to minimise any neck pain. The provision of TIS also
facilitates resting the neck during tilting (Angsupaisal et al., 2015).
Most of our users had spasticity, which was problematic in
13 of them. Spasticity due to poor posture is managed through
appropriate seating which probably explains the high use of
SS in this study. Contractures are widespread in adults with
CP but the majority of contractures can be “accommodated”
through the chair and SS.
Hip problems are widespread in CP (Novak et al., 2012). In
children, management relates to the underlying cause and
EPIOCs with SS may help to prevent hip problems from
developing/progressing (Pountney, Mandy, Green, & Gard,
2002) while allowing for growth. Consequently, all users,
except one adult with hip problems, in this cohort were
provided with SS. This indicates that hip assessment is a key
clinical focus those with CP and is likely to partly explain the
use of CAPS 11 seating systems in this cohort.
Athetosis is challenging for wheelchair providers as
prevention of limb trauma through the athetoid movements
is needed, e.g., by providing padding over projecting metal
surfaces. Athetosis was not contraindicated for EPIOC provi-
sion for 23 users who completed the assessment safely.
Fatigue was not an issue for this cohort as EPIOCs
eliminate energy expenditure through impaired walking or
by self-propelling a manual chair. Just over half of this cohort
was provided with TIS—a widely used fatigue management
strategy (Dicianno et al., 2015).
ACFs
Nearly two-thirds of our users had ACFs potentially influen-
cing the EPIOC prescription which may be critical for service
funders. The number of ACFs increases with CP GMFCS levels
IV and V and in those with specific neurologic profiles such as
spastic tetraplegia and dyskinesia (Shevell et al., 2009). We have
shown there is similar impact in adults with CP, compounded
by ACFs associated with aging, indicating that practitioners
should be proactive in responding to age-associated features
(Janicki et al., 2008).
There is ambiguity concerning what clinical features are
associated with CP and what are comorbidities. Thus epilepsy
is noted to be a feature of CP by Novak et al. (2012) but a
comorbidity by Shevell et al. (2009). Likewise it is debateable
if contractures are a feature of CP or if they are a consequence
of long-term disability—dilemmas already noted in multiple
sclerosis (De Souza & Frank, 2015). In determining which
ACFs were associated with CP we used published clinical
prognostic recommendations (Novak et al., 2012).
Comorbidity
We used a straightforward count of comorbidity (Carmona,
2014) and confirm its increased occurrence in CP (Liptak,
2008). Similar to other reports, we found a few users with
comorbid congenital anomalies (Rankin et al., 2010).
Although we noted only one user with encephalopathy, it has
been reported previously (Kyriakopoulos, Oskoui, Dagenais, &
Shevell, 2013). Hydrocephalus was coded as a comorbidity as it
has been considered a “chance finding” in CP (Rankin et al.,
2010). We noted depression as a comorbidity (Sangha, Stucki,
Liang, Fossel, & Katz, 2003) whilst recognizing it may relate to
long term disablement.
Features secondary to severe disability
A clinically significant (kypho)scoliosis was the commonest
complication of disability found (Graham, Ang, Johnson,
Torode, & Simpson, 2014). Most of our users were aged over
18 suggesting that higher levels of disability increase the risk of
developing scoliosis (Persson-Bunke, Hagglund, Lauge-Pedersen,
Ma, &Westbom, 2012). All but two users with a (kypho)scoliosis
were provided with SS and whilst postural stability can be sup-
ported by SS (Angsupaisal et al., 2015), this may sacrifice upper
trunk function which may not be the choice of the user.
Pressure sores, thromboembolic disease, oedema/cellulitis,
and osteoporosis are all preventable complications of disability
72 A. O. FRANK AND L. H. DE SOUZA
and the incidence in this cohort was low. This finding does not
negate the seriousness of these complications and vigilance is
needed to identify those at risk. Modest dependent oedema can
be assisted with TIS, elevating leg rests, and users should elevate
their legs at night.
Wheelchair features and seating
CP users were provided with SS more frequently than any
other diagnostic group from our main study (Frank & De
Souza, 2013). The clinical reasoning stems from evidence that
maintaining adequate seating and postural control is a prior-
ity for preventing deformity (Noonan et al., 2004), to facilitate
activities of daily living (Lacoste et al., 2009), and optimize
pain management (Noonan et al., 2004). CAPS II seats were
often utilized for younger users to maintain optimal hip
position, inhibit development of scoliosis, and allow for
growth. Where CAPS II was inappropriate but bespoke pres-
sure reduction was needed, carved foam seating was provided
for those at risk of skin breakdown (Apatsidis, Solomonidis, &
Michael, 2002). All but 12 users were provided with pressure
reduction cushions/seating, thus minimizing the likelihood of
pressure sores and maximizing comfort.
TIS was provided to just over half the users, irrespective of
age, reflecting common practice (Frank & De Souza, 2013).
TIS benefits users with poor head control, discomfort, fatigue,
and/or pain (Dicianno et al., 2015; Frank et al., 2012).
We found that most EPIOC users drive safely using standard
control systems but 16 were unable to do so. They were provided
with bespoke controls to facilitate driving independently and
interface with other AT, e.g., environmental controls. For those
with CP needing complex controls, an assessment regarding
additional AT is recommended.
Supporting individuals with CP is costly (Kruse et al.,
2009). Our finding that a high proportion of users were
given SS, TIS, and/or both, together with modifications to
control systems, as part of condition management has cost
implications for service payers.
Safety
Safety issues exist for all EPIOC users irrespective of age or
diagnosis (Evans et al., 2007; Frank, Neophytou, Frank, & De
Souza, 2010). Assessments minimize risk for users and the
public. Those with severe visual impairment, uncertain epilepsy
control, and learning disabilities are unlikely to fulfill eligibility
criteria. Our cohort had one with vision impairment, eight with
epilepsy and four with learning disability, all of whom fulfilled
eligibility criteria. For those with epilepsy, the criteria were
identical as for driving cars (Driver and Vehicle Licensing
Authority, 2014). For those with visual impairments, the clinic
and driving assessments seemed adequate.
Strengths and limitations of the study
A major strength of this study was the eligibility criteria,
restriction of EPIOC provision to those with GMFCS levels
IV and V. This cohort included all ages apart from pre-school
age children—a limitation as a complete picture is not
provided of EPIOC provision in those severely affected by
CP. This, together with severe disability without intellectual
impairment, does not permit comparison with other CP
cohorts. Research on adults with CP is currently sparse and
our older subgroup provides comparisons for future studies.
All users were seen by the same multidisciplinary team
with expertise in wheelchair prescription for users with severe
and/or multiple impairments. Thus expertise was consistently
applied in prescribing EPIOCs.
This study is likely to under-report ACFs, as the data were
mostly obtained via referral letters and patient histories; and
as case note reviews are less comprehensive than prospective
data. Nonetheless these data are more objective than that
relying purely on patient self-report surveys.
Our sample does not include those who purchased
wheelchairs privately or through charitable funding. This
limitation is more likely to influence our findings in children/
young adults as sources of charitable funding are greater for
these users.
Findings were limited by missing TIS information and the
medical profiles. Prospective studies are needed to obtain
complete comorbidity information.
Conclusion
Powered wheelchair prescription has an important therapeutic
role in clinical management in addition to enhancing mobility,
independence, and participation. It is influenced by the
underlying neuromuscular features of CP, comorbidities and
conditions related to long-term disability, and requires a
model of rehabilitation which is holistic rather than a disease
management orientated approach.
Clinical features such as spasticity and problematic pain
appeared less well managed in adults than in children and
have consequences for EPIOC provision especially with regard
to type of chair and seating prescription. Children were more
frequently provided with the additional wheelchairs features of
TIS, SS, and complex controls. Conversely, adults experienced
more problematic pain, more problematic spasticity, and more
comorbidities. The impact on EPIOC provision of ACFs in
adults with CP requires further study.
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